Q-omics provides the consensus-scored RSL24D1P6 profile across patient tissues and cancer cell-line models. RSL24D1P6 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RSL24D1P6 is differentially expressed in 10, with the highest sampling consensus in CHOL. Additionally, RSL24D1P6 RNA expression shows 18,320 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, CHOL, and THYM as cancer lineages where RSL24D1P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RSL24D1P6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RSL24D1P6 survival associations across molecular data types. RSL24D1P6 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RSL24D1P6 RNA expression–survival associations across cancer types. High RSL24D1P6 expression shows unfavorable associations in LIHC and UCEC, but favorable associations in HNSC, SKCM, LGG and UCS. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify HNSC as the clearest survival context for RSL24D1P6 RNA expression.
This table summarizes RSL24D1P6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for RSL24D1P6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RSL24D1P6 shows lower tumor expression in UCEC and LUAD and higher tumor expression in CHOL, LIHC, KIRP and READ. The CHOL box plot shows higher RSL24D1P6 RNA expression in tumor versus normal tissue (log2 FC = +1.120, t-test p < 0.001).
This table shows molecular features associated with RSL24D1P6 in patient tissues and cancer cell lines. In patient samples, RSL24D1P6 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
